Glucose degradation and cytotoxicity in PD fluids.
Wieslander
A
A
Department of Nephrology, University Hospital of Lund, Sweden.
Lindén
T
T
D000818:Animals; D001711:Biotransformation; D002455:Cell Division / Q000187:drug effects*; D002470:Cell Survival / Q000187:drug effects*; D015314:Dialysis Solutions / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D005950:Glucose Solution, Hypertonic / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007375:Interleukin-1 / Q000378:metabolism; D008422:Materials Testing; D010530:Peritoneal Dialysis; D010531:Peritoneal Dialysis, Continuous Ambulatory; D017382:Reactive Oxygen Species / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D015314:Dialysis Solutions; D005950:Glucose Solution, Hypertonic; D007375:Interleukin-1; D017382:Reactive Oxygen Species; D014409:Tumor Necrosis Factor-alpha